Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 6-month Randomized, Double-blind, Parallel-group, Multicentre, Placebo-controlled Phase II Study to Compare Anti-asthmatic Effect and Safety of Esomeprazole (Nexium®) 40 mg Twice Daily or 40 mg Once Daily With Placebo in Adults With Asthma

NCT00317044 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00317044
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00317044 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 6-month Randomized, Double-blind, Parallel-group, Multicentre, Placebo-controlled Phase II Study to Compare Anti-asthmatic Effect and Safety of Esomeprazole (Nexium®) 40 mg Twice Daily or 40 mg Once Daily With Placebo in Adults With Asthma
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2006
Completion date
July 31, 2008
Enrollment
961 (actual)
Sites
130

Conditions

As the registry lists them; a condition with its own page is linked.

asthma, gerd